EA200100806A1 - Производные алкинилсодержащих гидроксамовых кислот, способы их получения и применение указанных веществ в качестве ингибиторов матриксной металлопротеиназы (ммр) и фно-альфа-конвертирующего фермента (tace) - Google Patents
Производные алкинилсодержащих гидроксамовых кислот, способы их получения и применение указанных веществ в качестве ингибиторов матриксной металлопротеиназы (ммр) и фно-альфа-конвертирующего фермента (tace)Info
- Publication number
- EA200100806A1 EA200100806A1 EA200100806A EA200100806A EA200100806A1 EA 200100806 A1 EA200100806 A1 EA 200100806A1 EA 200100806 A EA200100806 A EA 200100806A EA 200100806 A EA200100806 A EA 200100806A EA 200100806 A1 EA200100806 A1 EA 200100806A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- carbon atoms
- atoms
- heteroaryl
- aryl
- alkyl
- Prior art date
Links
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical class C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 title 1
- 229940019748 antifibrinolytic proteinase inhibitors Drugs 0.000 title 1
- 239000011159 matrix material Substances 0.000 title 1
- 239000002184 metal Substances 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 title 1
- 238000011084 recovery Methods 0.000 title 1
- 239000000126 substance Substances 0.000 title 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 12
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 4
- 125000004429 atom Chemical group 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 208000020084 Bone disease Diseases 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 208000037357 HIV infectious disease Diseases 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000025865 Ulcer Diseases 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 201000001245 periodontitis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
- 230000036269 ulceration Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
- C07D211/66—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having a hetero atom as the second substituent in position 4
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23803899A | 1999-01-27 | 1999-01-27 | |
| PCT/US2000/001864 WO2000044723A1 (en) | 1999-01-27 | 2000-01-27 | Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors/tnf-alpha converting enzyme (tace) inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA200100806A1 true EA200100806A1 (ru) | 2002-08-29 |
Family
ID=22896246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200100806A EA200100806A1 (ru) | 1999-01-27 | 2000-01-27 | Производные алкинилсодержащих гидроксамовых кислот, способы их получения и применение указанных веществ в качестве ингибиторов матриксной металлопротеиназы (ммр) и фно-альфа-конвертирующего фермента (tace) |
Country Status (13)
| Country | Link |
|---|---|
| JP (1) | JP2002535390A (xx) |
| KR (1) | KR20010101732A (xx) |
| AR (1) | AR035312A1 (xx) |
| AT (1) | ATE309986T1 (xx) |
| AU (1) | AU769418B2 (xx) |
| CA (1) | CA2356313A1 (xx) |
| CZ (1) | CZ20012711A3 (xx) |
| DE (1) | DE60024056D1 (xx) |
| EA (1) | EA200100806A1 (xx) |
| HU (1) | HUP0200223A3 (xx) |
| IL (1) | IL144345A0 (xx) |
| NZ (1) | NZ512566A (xx) |
| ZA (1) | ZA200105222B (xx) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4566006B2 (ja) * | 2002-12-26 | 2010-10-20 | カルナバイオサイエンス株式会社 | アルキニル基置換アザ糖誘導体およびそれを有効成分とする薬剤 |
| CA2656398A1 (en) * | 2006-06-30 | 2008-01-10 | Schering Corporation | Substituted piperidines that increase p53 activity and the uses thereof |
| AU2009254959B2 (en) * | 2008-06-02 | 2014-01-30 | Cipla Limited | Processes for the synthesis of levocetirizine and intermediates for use therein |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT970046E (pt) * | 1997-02-27 | 2004-04-30 | Wyeth Corp | N-hidroxi-2-(alquil, aril, ou heteroaril sulfanil, sulfinil ou sulfonil)-alquil, aril ou heteroaril amidas substituidas em 3 como inibidores de metaloproteinase de matriz |
| EP1054858A1 (en) * | 1998-02-19 | 2000-11-29 | American Cyanamid Company | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted-alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors |
-
2000
- 2000-01-26 AR ARP000100327A patent/AR035312A1/es not_active Application Discontinuation
- 2000-01-27 CZ CZ20012711A patent/CZ20012711A3/cs unknown
- 2000-01-27 AU AU26305/00A patent/AU769418B2/en not_active Ceased
- 2000-01-27 EA EA200100806A patent/EA200100806A1/ru unknown
- 2000-01-27 DE DE60024056T patent/DE60024056D1/de not_active Expired - Lifetime
- 2000-01-27 AT AT00904569T patent/ATE309986T1/de not_active IP Right Cessation
- 2000-01-27 NZ NZ512566A patent/NZ512566A/xx unknown
- 2000-01-27 IL IL14434500A patent/IL144345A0/xx unknown
- 2000-01-27 KR KR1020017009432A patent/KR20010101732A/ko not_active Application Discontinuation
- 2000-01-27 HU HU0200223A patent/HUP0200223A3/hu unknown
- 2000-01-27 CA CA002356313A patent/CA2356313A1/en not_active Abandoned
- 2000-01-27 JP JP2000595979A patent/JP2002535390A/ja active Pending
-
2001
- 2001-06-25 ZA ZA200105222A patent/ZA200105222B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ512566A (en) | 2004-02-27 |
| CA2356313A1 (en) | 2000-08-03 |
| DE60024056D1 (de) | 2005-12-22 |
| CZ20012711A3 (cs) | 2002-05-15 |
| KR20010101732A (ko) | 2001-11-14 |
| AR035312A1 (es) | 2004-05-12 |
| JP2002535390A (ja) | 2002-10-22 |
| ZA200105222B (en) | 2002-09-25 |
| IL144345A0 (en) | 2002-05-23 |
| ATE309986T1 (de) | 2005-12-15 |
| AU769418B2 (en) | 2004-01-29 |
| AU2630500A (en) | 2000-08-18 |
| HUP0200223A3 (en) | 2002-12-28 |
| HUP0200223A2 (en) | 2002-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LU91587I2 (fr) | Agomélatine et ses dérivés pharmaceutiquement acceptables (VALDOXAN) | |
| HUP0000641A2 (hu) | orto-Szulfonamido-aril-hidroxámsav-származékok, mátrix metalloprotenáz, valamint TACE-gátlóként való alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények | |
| EA200600358A1 (ru) | Фенил- или пиридиламидные соединения в качестве антагонистов простагландина е2 | |
| DK463986A (da) | (n-substitueret-2-hydroxy)-benzamider og n-substitueret-2-hydroxy-alfa-oxo-benzenacetamider, fremgangsmaade til deres fremstilling og farmaceutiske kompositioner indeholdende forbindelserne | |
| DK114783D0 (da) | Hidtil ukendte forbindelser, fremgangsmader til deres fremstilling samt deres anvendelse som laegemidler | |
| NO900991L (no) | Analogifremgangsmaate for fremstilling av terapeutisk virksomme 2-(l-piperazinyl)-4-fenylcycloalkanopyridin-derivater | |
| EA200600509A1 (ru) | Соединения пиримидотиофена | |
| EA200301216A1 (ru) | Замещенные хинуклидинами мультициклические гетероарилы для лечения заболевания | |
| EA200400023A1 (ru) | Ингибиторы вич-протеазы, содержащие их композиции, их фармацевтическое использование и материалы для их синтеза | |
| EA200401053A1 (ru) | Оксо-азабициклические соединения | |
| SE8303824D0 (sv) | N-imidazolyl derivatives of bicyclic compounds and process for their preparation | |
| CY1109085T1 (el) | Νεα αλατα | |
| MX9303145A (es) | 7-(2-aminoetil)benzotiazolonas. | |
| DK0484223T3 (da) | 3-cyclopropanamider, deres tautomere former og deres salte samt en fremgangsmåde til deres fremstilling, deres anvendelse som lægemidler og præparater med indhold deraf | |
| KR950011444A (ko) | 갈란타민 유도체, 이의 제조방법 및 약제로서의 이의 용도 | |
| EA200100059A3 (ru) | Новые бензолсульфонамидные производные, способ их получения и содержащие их фармацевтические композиции | |
| EA200100806A1 (ru) | Производные алкинилсодержащих гидроксамовых кислот, способы их получения и применение указанных веществ в качестве ингибиторов матриксной металлопротеиназы (ммр) и фно-альфа-конвертирующего фермента (tace) | |
| DK384485A (da) | 1,6-naphthyridinderivater med kardilaterende virkning | |
| DE3167049D1 (de) | Diphenylbutyl-1-acylpiperazines | |
| EA199900156A1 (ru) | Новые производные эритромицина, способ их получения и их применение в качестве медикаментов | |
| DK1205476T3 (da) | Fremgangsmåde til syntese af N-(mercaptoacyl)-aminosyrederivater ud fra alfa-substituerede acrylsyrer | |
| EA200200352A1 (ru) | Фенил- и пиридил-тетрагидропиридины, обладающие ингибирующей активностью в отношении фактора некроза опухоли (фно) | |
| CA2364199A1 (fr) | Nouveaux derives bicycliques d'amino-pyrazinones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| DK1178047T3 (da) | Diazabicyclooctanderivater og terapeutiske anvendelser deraf | |
| EA200200665A1 (ru) | Новые соединения бензолсульфонамида, способ их получения и фармацевтические композиции, их содержащие |